Prognosis
Covid Drugs From Lilly, Regeneron Raise Access, Timing Concerns
- Doses are severely limited as U.S. logs record infections
- Antibody therapies aimed at keeping mild cases from worsening
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Powerful drugs recently authorized by the U.S. that may prevent those at the earliest stages of Covid-19 from suffering severe disease present thorny new challenges, including who will get them and where they’ll be administered.